Dingell, Stupak mull FDA inspection law

U.S. Reps. John Dingell, D-Mich., and Bart Stupak, D-Mich., are pondering tougher laws after the FDA failed to follow its own guidelines on the inspection of foreign drug plants. Stupak said he will look into legislation that makes it illegal to distribute a drug in the U.S. from a facility that has not undergone FDA inspection, in light of the agency's failure to inspect a Chinese plant that makes the active ingredient in Baxter's blood thinner heparin.

View Full Article in:

Boston Globe (tiered subscription model), The · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Chicago, IL
Senior Manager, Compliance
Fremont, CA
Manager, Business Conduct
Foster City, CA
Product Patent Attorney
Foster City, CA
Employment Counsel
Foster City, CA